- Cagrilintide is a long-acting amylin-receptor agonist studied for satiety and slowed gastric emptying, effects complementary to GLP-1 signaling.
- Its trials, including the semaglutide combination known as CagriSema, enrolled many women, but female-specific effects and dosing have not been separately established.
- Cagrilintide is investigational, not approved, and there is no lactation data and no basis for use in pregnancy.
Cagrilintide approaches weight and metabolic research from a different receptor than the incretin agents that dominate the conversation. It is a long-acting synthetic analogue of amylin, a pancreatic hormone that works alongside insulin in glucose and appetite regulation. Its lipidated, C-terminally amidated structure gives it an extended profile, which makes it a convenient research material for studies of amylin-pathway signaling and, increasingly, for combination work.
For a database written around female physiology, cagrilintide lands in the same place as most metabolic compounds in active development: women are in the trials, and female-specific questions have not been pulled out and answered. It is worth being precise about both halves of that.
The amylin axis
In preclinical and cell-based models, cagrilintide has been studied for its activity at amylin and calcitonin receptors and for its role in nutrient-sensing and energy-balance pathways, including its interactions with incretin signaling. As an amylin-receptor agonist it is studied for promoting satiety and slowing gastric emptying, effects positioned as complementary to GLP-1 signaling rather than duplicative of it.
CagriSema and the combination angle
Much of the clinical interest in cagrilintide comes from pairing it with the GLP-1 analogue semaglutide, a combination studied under the name CagriSema, on a rationale of complementary mechanisms: amylin-pathway satiety signaling alongside incretin signaling. This remains investigational research rather than an approved product; the combination framing does not change the compound's regulatory status, and nothing here is a recommendation or a benefit claim.
Women in the trials, questions unanswered
Cagrilintide trials enroll many women. But female-specific effects and dosing have not been separately established, so the sex-difference state is no-evidence rather than demonstrated similarity. The compound remains investigational, and the analyses that would answer female-specific questions have not been published in a form the record can rely on.
- Menstrual cycle interactions: no published analysis of cycle-phase effects.
- Pregnancy and lactation: an investigational weight-management agent is not for use in pregnancy, and there is no lactation data.
- Hormonal interactions: delayed gastric emptying could in principle affect oral-drug absorption, but a contraceptive or hormonal interaction has not been characterized for cagrilintide specifically.
- Perimenopause and menopause: no perimenopausal or menopausal-specific analysis is established.
- Sex differences: trials enrolled women, but female-specific effects and dosing are not separately established.
As with other agents that slow gastric emptying, altered absorption of oral medications is a plausible mechanism, but for cagrilintide specifically it is unstudied. We record it as an open question rather than a demonstrated interaction or a cleared risk. On dose, cagrilintide has been studied with investigational once-weekly subcutaneous dosing in trials, which we report as a literature figure only.
This site does not publish personal dosing. Trial dosing figures describe the research record for context; they are not a protocol or medical advice.
Cagrilintide is a mechanistically distinct entry, an amylin analogue rather than another incretin agent, and it has women in its trials. What it lacks is the sex-stratified analysis that would let anyone speak to female-specific effects, and it remains investigational throughout. The structured, field-by-field review sits on the compound profile at cagrilintide.